Sign up
Pharma Capital

PharmAust to lift cash position following appointment of new executive team

The halt will remain in place until Wednesday 6th December 2017.
The company's shares are in pre-open

PharmAust Ltd (ASX:PAA) is a clinical-stage oncology company with its lead product being Monepantel(MPL) – a repurposed drug already approved for veterinary use.

PharmAust has a strategy targeting MPL for both human and vet applications.

Drug repurposing can be a capital efficient path to market.

The company recently appointed Dr Angela Frimberger and Dr Christian Schirvel, who are international opinion leaders in the field of animal health to advise and assist with its veterinary cancer program.

To fund the next steps PharmAust is now heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Wednesday 6th December 2017, or earlier if an announcement is made to the market.

Register here to be notified of future PAA Company articles
View full PAA profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.